Anglo-Swedish drugmaker AstraZeneca said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus.
The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus within the past eight days.
AZD7442 reduced the risk of developing symptomatic COVID-19 by 33 percent compared to a placebo, which was not statistically significant, the company reported.
“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” Mene Pangalos, AstraZeneca executive vice president, said in a statement.
AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease.
The monoclonal antibody therapy belongs to a class of drugs which mimic natural antibodies the body produces to fight off the infection.
Rivals Regeneron Pharmaceuticals Inc and Eli Lilly & Co have both developed monoclonal antibody therapies which have been authorized for use in the United States to treat patients infected with the virus.. The European Medicines Agency (EMA) has approved Regeneron’s therapy and is reviewing similar drugs from Eli Lilly, Celltrion and one developed by GlaxoSmithKline and Vir Biotechnology Inc.
AstraZeneca in October enlisted Swiss contract manufacturer Lonza to produce the antibody drug in Portsmouth, New Hampshire, starting in the first half of 2021.
AZD7442 is being developed with support from the US government. AstraZeneca in March announced a deal with the US government to supply up to half a million doses of AZD7442. The company said on Tuesday it is now in talks with the US government regarding next steps on the deal.
Study shows AstraZeneca COVID-19 vaccine works well as third booster: FTThe COVID-19 vaccine of AstraZeneca Plc and Oxford University works well as a third booster dose, stepping up antibodies to the coronavirus spike ... Coronavirus
Canada extends shelf life of AstraZeneca COVID-19 jab by one monthCanadian health authorities announced Saturday they were pushing back the expiration date on nearly 50,000 doses of AstraZeneca coronavirus vaccine by ... Coronavirus
AstraZeneca vaccine should be halted for over-60s: EMACountries should avoid giving the AstraZeneca coronavirus vaccine to people over 60 in addition to younger age groups, the head of the EU drug ... Coronavirus
Russia declines to approve combined AstraZeneca, Sputnik V COVID-19 vaccine trialsThe Russian health ministry’s ethical committee has declined to approve clinical trials in Russia combining a British shot from AstraZeneca and Oxford ... Coronavirus